

Consensus of Analysts' Estimates > Pre-Q3 2025



The consensus is the median of analyst estimates which are compiled and calculated by Vara I..... based on the projections made by analysts covering Solvay. Any opinions, estimates or forecasts regarding Solvay's performance made by these analysts and therefore also the consensus figures are theirs alone and do not represent opinions or forecasts of Solvay or its Management. By making this consensus information of its results available on a quarterly basis, Solvay does not mean or otherwise imply to endorse such information.

Poll date	Participants	Median TP
13/10/25	17	29.00
BUY	HOLD	SELL
41%	35%	24%

KPI expressed in € million except stated DPS (€) and ROCE

	Actuals									Estimates				
	FY 2022 published	FY 2023 published	Q1 2024	Q2 2024	Q3 2024 A	Q4 2024 A	FY 2024 A	Q1 2025 A	Q2 2025 A	Q3 2025 E	Q4 2025 E	FY 2025 E	FY 2026 E	FY 2027 E
<i>All figures are "Underlying" and "from continuing operations" (1)</i>														
Net sales	5,539	4,880	1,201	1,194	1,156	1,134	4,686	1,122	1,102	1,060	1,043	4,314	4,369	4,524
Basic Chemicals, Sales	2,994	2,726	715	708	706	712	2,842	672	667	661	663	2,666	2,675	2,770
Performance Chemicals, Sales	2,542	2,148	484	483	448	419	1,834	450	434	405	388	1,678	1,711	1,771
Corporate, Sales	4	6	3	2	3	2	10	0	0	3	2	5	5	5
EBITDA	1,359	1,246	265	272	259	256	1,052	250	230	203	200	885	924	1,003
Basic Chemicals, EBITDA (2)	859	916	202	194	181	209	786	162	141	148	157	605	653	695
Performance Chemicals, EBITDA (2)	414	405	80	101	79	64	324	94	104	79	74	351	344	356
Corporate, EBITDA	86	-75	-16	-23	-2	-18	-58	-6	-15	-25	-29	-75	-83	-60
EBIT	1,038	926	184	197	179	172	732	172	150	122	122	563	606	675
Net Profit from continuing operations	740	588	119	116	108	102	445	102	99	68	70	339	363	410
Gross DPS (€)		2.43					2.43			-	-	2.43	2.43	2.46
Capex	-380	-450	-59	-48	-84	-163	-355	-70	-63	-	-	-289	-308	-323
Free cash flow to Solvay shareholders from continuing operations	479	561	123	120	74	44	361	42	54	-	-	271	292	350
Net Financial Debt		1,489	1,587	1,568	1,546		1,544	1,725	1,856	-	-	1,662	1,630	1,573
ROCE (in %)	22.9%	20.4%	19.8%	17.6%	17.3%		17.6%	17.2%	16.0%	-	-	13.9%	15.1%	16.3%

(1) For full disclosure and definition of Underlying alternative metrics on a proforma basis, please refer to the glossary attached in the Financial reports.

(2) The 2023 figures were restated to reflect the transfer of eH2O2 activities from Special Chem to Peroxides on January 1, 2024.